세계의 주사기 시장 규모는 2024년에 211억 달러에 달했습니다. 향후 시장은 2033년까지 387억 달러에 달하며, 2025-2033년에 6.99%의 성장률(CAGR)을 보일 것으로 예측됩니다. 개인에 대한 신속하고 안전한 백신 접종을 장려하는 정부기관에 의한 우호적 정책이 시장을 활성화하는 요인의 하나입니다.
주요 시장 성장 촉진요인 : 만성질환의 유병률 증가는 주로 시장을 강화하고 있습니다. 또한 외과적 개입을 받는 사람들이 증가함에 따라 마취제 투여를 위한 일회용 주사기에 대한 선호도가 높아지는 것도 중요한 성장 촉진요인으로 작용하고 있습니다.
주요 시장 동향 : 주요 기업이 의료진과 환자들 사이에서 감염을 피하면서 효율적으로 멸균 수술을 수행하는 데 주력하고 있는 것은 시장을 확대하는 새로운 동향 중 하나입니다. 이와는 별도로 일회용 의료용품의 보급이 시장에 긍정적인 영향을 미치고 있습니다.
경쟁 구도 : 세계 시장의 유명 기업에는 B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Cardinal Health Inc., Gerresheimer AG, Hindustan 주사기 &Medical Devices Ltd., Nipro Corporation, Pfizer Inc., Retractable Technologies Inc., Schott AG, Smiths Group plc, Terumo Corporation, Thomas Scientific LLC 등이 있습니다.
지역적 동향 : 북미는 안전 및 감염 통제를 위한 정부 기관의 많은 구상 도입으로 인해 시장에서 뚜렷한 우위를 보이고 있습니다. 또한 첨단 제조 공정은 예측 기간 중 이 지역 시장을 활성화할 것으로 예측됩니다.
과제와 기회: 시장을 저해하는 주요 요인 중 하나는 바늘에 찔리는 손상과 관련된 위험입니다. 그러나 적절한 사용 및 폐기 방법을 보장하기 위해 의료 종사자를 위한 종합적인 교육 프로그램의 시작은 향후 수년간 세계 시장에 활력을 불어넣을 것으로 예측됩니다.
첨단 주사기에 대한 수요
주사기의 안전성과 기능을 향상시키는 새로운 첨단 기술의 도입은 주사기 시장 전망에 긍정적인 영향을 미치고 있습니다. 예를 들어 2024년 3월, 자동 비활성화 일회용 주사기 제조업체 중 하나인 Hindustan 주사기 and Medical Devices(HMD)는 바늘에 찔리는 부상을 최소화하는 일회용 안전 주사기 Dispojekt를 발표했습니다. 이 외에도 2024년 5월 독일에 본사를 둔 헬스케어 및 의약품 포장 기업 Gerresheimer는 멕시코 Queretaro 시설의 확장을 발표하며 북미 시장 수요에 대응하기 위해 RTF(Ready-to-Fill) 주사기 생산 능력을 강화할 것이라고 밝혔습니다. 또한 재택치료에 대한 선호도 변화와 생물제제의 인기 상승도 시장을 촉진하고 있습니다. 예를 들어 2024년 3월, 의약품 봉쇄 솔루션 및 전달 시스템 프로바이더 중 하나인 SCHOTT Pharma는 mRNA 의약품의 냉장 보관 및 운송에 필요한 프리필러블 폴리머 주사기를 제조하는 미국 최초의 시설을 윌슨에 건설했습니다. 했습니다. 이 시설은 또한 당뇨병 및 비만 치료제와 같은 GLP-1 치료제를 위한 유리 프리필러블 주사기를 생산할 수 있습니다.
만성질환의 만연
암, 당뇨병, 심혈관 질환 등 만성질환 증가로 주사기를 통한 정기적이고 정확한 투약의 필요성이 높아지고 있습니다. 유럽마약 및 약물중독감시센터(EMCDDA)와 유럽질병예방통제센터(ECDC)가 2023년 11월에 발표한 보고서에서는 개인 간 감염을 예방하기 위한 주사바늘 및 주사기 프로그램(NSP)과 같은 개입의 효과성을 평가했습니다. 또한 당뇨병의 일상적인 관리를 위해 인슐린 주사기가 널리 사용되고 있는 것도 시장을 강화하고 있습니다. 예를 들어 텔모인디아는 2023년 11월 정기적인 인슐린 주사가 필요한 환자를 위한 무균 전달 장비인 인슐린 주사기를 출시했습니다. 이 제품은 텔모 메디컬 케어 솔루션의 라이프케어 솔루션 사업부에 추가된 제품입니다. 이 주사기는 인슐린 주사가 필요한 환자들을 위해 3단계의 초첨 바늘과 고급 실리콘 표면으로 특별히 설계되어 환자들에게 더 부드럽고 편안한 느낌을 줍니다. 또한 플런저 유지 기술을 채택한 독자적인 기능으로 낭비와 누출을 방지할 수 있습니다. 또한 미국 당뇨병 협회는 미국에서 수백만 명이 인슐린 주사를 필요로 하는 것으로 추산하고 있으며, 이는 신뢰할 수 있고 사용하기 쉬운 주사기에 대한 수요를 촉진하고 있습니다.
안전에 대한 관심 증가
의료 현장의 감염 관리 개선에 대한 관심이 높아지면서 첨단 주사기 기술의 채택이 가속화되고 있습니다. 예를 들어 2024년 5월, 저분자, 생물제제 및 백신의 무균 주사제 위탁 생산 업체 중 하나인 Grand River Aseptic Manufacturing(GRAM)은 업계의 생물제제 파이프라인 증가와 환자 자가 투여를 위한 첨단 약물전달 시스템의 성장에 대응하기 위해 주사기 및 카트리지 생산 능력을 확대했습니다. 주사기 및 카트리지 생산 능력을 확대했습니다. 이와는 별도로, 바늘에 찔리는 손상을 방지하기 위해 안전 주사기 사용을 의무화하는 정부 기관의 엄격한 규제 시행은 또 다른 중요한 성장 촉진요인으로 작용하고 있습니다. 예를 들어 2024년 3월 미국 식품의약국(FDA)은 미국내 의료 기관에 중국산 미승인 플라스틱 주사기 사용을 즉시 중단할 것을 권고했습니다. 이 권고안은 프리필드 시린지, 유리 주사기, 경구 및 국소 주사기에는 적용되지 않습니다. 이에 따라 주요 제조업체들은 필수적인 고품질 의료용 제품을 출시하여 대응하고 있으며, 향후 시장은 더욱 활성화될 것으로 보입니다. 예를 들어 의료 기술 기업 중 하나인 BD(Beckton Dickinson & Company)는 2024년 3월 고객의 요구에 부응하기 위해 주사기 국내 생산을 미국 네브래스카주와 코네티컷주 시설로 확대했습니다.
The global syringes market size reached USD 21.1 Billion in 2024. Looking forward, the market is expected to reach USD 38.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.99% during 2025-2033. Favorable policies by government bodies for encouraging the fast and safe vaccination of individuals are among the factors fueling the market.
Major Market Drivers: The rising prevalence of chronic diseases is primarily bolstering the market. Moreover, the growing preference for single-use syringes to deliver anesthetics, owing to the increasing number of individuals who are undergoing surgical interventions, is also acting as another significant growth-inducing factor.
Key Market Trends: The inflating focus of key players on efficient sterilizing surgery while avoiding infections among healthcare practitioners and patients is one of the emerging trends augmenting the market. Apart from this, the widespread popularity of disposable medical supplies is further positively influencing the market.
Competitive Landscape: Some of the prominent companies in the global market include B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, Cardinal Health Inc., Gerresheimer AG, Hindustan Syringes & Medical Devices Ltd., Nipro Corporation, Pfizer Inc., Retractable Technologies Inc., Schott AG, Smiths Group plc, Terumo Corporation, and Thomas Scientific LLC, among many others.
Geographical Trends: North America exhibits a clear dominance in the market, owing to the introduction of numerous initiatives by government bodies for safety and infection control. Furthermore, advanced manufacturing processes will continue to fuel the regional market over the forecasted period.
Challenges and Opportunities: One of the key factors hindering the market is the risk associated with needlestick injuries. However, the launch of comprehensive training programs for healthcare professionals to ensure proper usage and disposal practices is expected to catalyze the global market in the coming years.
Demand for Advanced Syringes
The introduction of novel advancements for enhancing the safety and functionality of syringes is positively influencing the syringes market outlook. For example, in March 2024, Hindustan Syringes and Medical Devices (HMD), one of the leading manufacturers of auto-disable and disposable syringes, introduced Dispojekt, an indigenous single-use safety syringe to minimize instances of needle stick injuries. Besides this, in May 2024, Gerresheimer, a healthcare and pharmaceutical packaging company based in Germany, announced the expansion of its Queretaro facility in Mexico to increase the production capacities for ready-to-fill (RTF) syringes, thereby catering to the market demand in North America. Additionally, the shifting preference towards home-based healthcare, along with the elevating popularity of biologics, is also propelling the market. For instance, in March 2024, SCHOTT Pharma, one of the pharmaceutical drug containment solutions and delivery systems providers, built its first U.S. facility in Wilson to manufacture pre-fillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications. The site can further produce glass pre-fillable syringes for GLP-1 therapies, such as those that treat diabetes or obesity.
Prevalence of Chronic Diseases
The growing incidences of chronic diseases, including cancer, diabetes, cardiovascular disorders, etc., are escalating the need for regular and precise medication delivery via syringes. The report published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the European Centre for Disease Prevention and Control (ECDC) in November 2023 assessed the effectiveness of interventions, including needle and syringe programs (NSPs), to prevent infections among individuals. Moreover, the widespread usage of insulin syringes for the daily management of diabetes is also bolstering the market. For instance, in November 2023, Terumo India launched an insulin syringe, a sterile delivery device for patients requiring regular insulin injections. It is the addition to the Life Care Solutions division of Terumo Medical Care Solutions. In line with this, specifically designed to have a 3-bevel super sharp needle with a high-grade silicone surface, the syringe is gentle and more comfortable for patients. Its unique feature with plunger retention technology avoids wastage and spillage. Furthermore, the American Diabetes Association estimated that millions of individuals in the U.S. require insulin injections, thereby driving the demand for reliable and user-friendly syringes.
Increasing Focus on Safety
There is a rising emphasis on improving infection control within healthcare settings, thereby stimulating the adoption of advanced syringe technologies. For example, in May 2024, Grand River Aseptic Manufacturing (GRAM), one of the sterile injectable contract manufacturers of small molecules, biologics, and vaccines, expanded its syringe and cartridge capacity to provide greater capacity for the industry's elevating biologics pipeline and the growth in advanced drug delivery systems for patient self-administration. Apart from this, the implementation of stringent regulations by government bodies that mandate the use of safety syringes to prevent needlestick injuries is further acting as a significant growth-inducing factor. For instance, in March 2024, the Food and Drug Administration (FDA) advised healthcare organizations in the U.S. to immediately transition away from using certain unauthorized plastic syringes made in China. The recommendations do not apply to pre-filled syringes, glass syringes, or syringes utilized for oral or topical purposes. Consequently, leading manufacturers are responding by introducing essential high-quality medical products, which will continue to bolster the market in the coming years. For example, in March 2024, BD (Becton, Dickinson and Company), one of the medical technology companies, elevated domestic manufacturing of syringes in Nebraska and Connecticut facilities, U.S., to cater to customer needs.
Among these, general syringes currently exhibit a clear dominance in the market
General syringes, essential tools in medical and healthcare settings, are continually evolving with advancements in technology and design aimed at improving safety, accuracy, and convenience. One of the notable launches is the Medtronic MiniMed 770G Insulin Pump System, which integrates advanced smart technology for precise insulin delivery, catering specifically to diabetes patients. General syringes improve user safety and reduce the risk of accidental injuries, thereby driving the segment's growth.
Currently, glass syringes hold the largest market share
Glass syringes are a crucial component in the medical field, valued for their durability, chemical resistance, and precise delivery capabilities. Unlike plastic syringes, they do not interact with the medications they contain, thereby making them ideal for administering highly reactive or sensitive drugs, such as biologics and certain vaccines. Their use is prominent in the pharmaceutical and biotechnology industries, where maintaining the integrity of the substance is paramount. In January 2024, Schreiner MediPharm, a Germany-based global provider of functional label solutions for the healthcare industry, developed barrier function labels that are generally designed to protect against oxygen ingress for drugs contained in COC syringes.
Disposable syringes hold the largest share in the market
Disposable syringes have become an indispensable tool in modern healthcare due to their convenience, affordability, and ability to reduce the risk of cross-contamination and infection significantly. Designed for single use, these syringes are typically made from plastic and come pre-sterilized, ensuring a high standard of hygiene. Their widespread adoption has been driven by health initiatives aiming to combat the spread of infectious diseases. According to the report by IMARC, the global disposable syringes market size reached US$ 15.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 27.4 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032.
The offline segment, which includes hospitals, clinics, and retail pharmacies, continues to dominate the market due to the immediate availability of products and the trust consumers place in physical purchases, especially for critical healthcare supplies. This traditional distribution method is bolstered by strong relationships between manufacturers and healthcare providers, ensuring a steady supply chain and reliable access to syringes. Conversely, the online segment is experiencing rapid growth, driven by the increasing adoption of e-commerce platforms in the healthcare sector. Online distribution offers significant advantages such as convenience, wider product availability, and competitive pricing, which are particularly appealing to individual consumers and smaller healthcare facilities. Major players in the market, like Becton Dickinson (BD) and Terumo, are leveraging digital platforms to expand their reach and enhance customer engagement.
Syringes play a critical role across various healthcare settings. In hospitals and clinics, they are indispensable for a wide range of procedures, from routine vaccinations and blood draws to administering medications and intravenous therapies. Their reliability and ease of use make them a staple in these high-demand environments. Diagnostic centers heavily rely on syringes for sample collection and diagnostic testing, ensuring accurate and sterile handling of specimens. Specialty centers, such as oncology and diabetes care facilities, utilize them for precise administration of treatments like chemotherapy and insulin, which require meticulous dosing and safety. Other settings, such as outpatient care centers and emergency medical services, depend on syringes for immediate, on-the-go medical interventions, highlighting their versatility and importance in diverse medical scenarios.
North America currently dominates the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
As per the syringes market overview, the rising prevalence of chronic diseases, increased vaccination efforts, and advancements in medical technology are acting as growth-inducing factors in North America. Moreover, in the United States, stringent safety regulations set by the Occupational Safety and Health Administration (OSHA) have led to the widespread adoption of safety-engineered syringes that are designed to minimize needlestick injuries and enhance user safety. Besides this, the American Diabetes Association estimated that millions of individuals in the U.S. require insulin injections, thereby escalating the use of reliable and user-friendly syringes. Furthermore, prominent players like Becton Dickinson (BD) and Novo Nordisk are leading the market with their advanced insulin delivery systems.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Gerresheimer, one of the healthcare and pharmaceutical packaging companies based in Germany, expanded its Queretaro capacity of ready-to-fill (RTF) syringes in Mexico.
March 2024: SCHOTT Pharma built its first U.S. facility to manufacture pre-fillable polymer syringes required to meet the need for deep-cold storage and transportation of mRNA medications.
March 2024: Hindustan Syringes and Medical Devices (HMD), one of the leading providers of auto-disable and disposable syringes, launched Dispojekt, an indigenous single-use safety syringe to minimize instances of needle stick injuries.